Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
This branded, FDA-approved GLP-1/GIP receptor agonist has helped numerous patients achieve significant, lasting weight loss results
This study is evaluating 24, 36, and 48 mg doses of GZR18 (Q2W) against placebo and 15 mg tirzepatide (QW)
Little Specks of Dust Dr
You may be a good candidate if: You meet BMI and/or metabolic criteria commonly used in medical weight management Youve already tried structured lifestyle changes and still struggle You are under the care of a primary physician Youre willing to have labs and regular follow-ups You understand these medications are medical tools, not cosmetic quick fixes You may not be a good candidate if you have a disordered eating history, are pregnant or breastfeeding, have specific endocrine or gastrointestinal diseases, or want a set it and forget it solution
Efpeglenatide Efpeglenatide is a novel, long-acting GLP-1 receptor agonist developed by Hanmi Pharmaceuticals (South Korea) utilizing the proprietary LAPSCOVERY (Long-Acting Protein/Peptide Discovery) technology platform
While everyone is different, many patients notice a decrease in appetite within the first week, with significant weight changes occurring over the first 3 to 6 months of a structured program
